 LEXINGTON, Mass., March 15, 2021 PRNewswire -- LogicBio Therapeutics, Inc. Nasdaq:LOGC LogicBio or the Company, a clinical- stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today reported financial results for the year ended December 31, 2020 and provided a business update. 